Drug intelligence / Profile preview

LTX-005

Development stage: Preclinical
Lead developer: Leal Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

LTX-005 is an antisense oligonucleotide (ASO) drug candidate developed by Leal Therapeutics. It targets the glutamate N-methyl-D-aspartate receptor (NMDAR), specifically the GluN2A subunit, and is being investigated for the treatment of refractory epilepsy and major depressive disorder/treatment-resistant depression (MDD/TRD). The drug is currently in preclinical development. Its mechanism involves modulation of glutamatergic neurotransmission via selective targeting of GluN2A-containing NMDARs, which are implicated in central nervous system disorders such as epilepsy and depression[1][2][3].

Targets

Glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) mRNA

Beyond the preview

Go deeper on LTX-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTX-005.

Explore the full profile